Infinity Pharmaceuticals, Inc. (INFI)
(Delayed Data from NSDQ)
$1.71 USD
+0.06 (3.64%)
Updated May 3, 2019 04:00 PM ET
After-Market: $1.72 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.71 USD
+0.06 (3.64%)
Updated May 3, 2019 04:00 PM ET
After-Market: $1.72 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Why Is Infinity Pharmaceuticals (INFI) Down 18.3% Since its Last Earnings Report?
by Zacks Equity Research
Infinity Pharmaceuticals (INFI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Infinity Pharmaceuticals (INFI) Could Shock the Market Soon
by Zacks Equity Research
Infinity Pharmaceuticals (INFI) sees solid earnings estimate revisions and looks poised to shock the market, and yet seems overlooked by the investors.
Karyopharm's Myeloma Candidate Gets Fast Track Designation
by Zacks Equity Research
The FDA grants a fast track status to Karyopharm's (KPTI) selinexor for treatment of multiple myeloma. Selinexor is also evaluated in several mid- and later-phase studies on multiple cancer indications.
FDA Prolongs Review Date for AbbVie Endometriosis Candidate
by Zacks Equity Research
The FDA extends the review period of NDA for AbbVie (ABBV) and partner Neurocrine Biosciences' endometriosis candidate, elagolix, by three months to third-quarter 2018.
Are Options Traders Betting on a Big Move in Infinity Pharmaceuticals (INFI) Stock?
by Zacks Equity Research
Investors in Infinity Pharmaceuticals (INFI) need to pay close attention to the stock based on moves in the options market lately.
Can The Uptrend Continue for Infinity Pharmaceuticals (INFI)?
by Zacks Equity Research
Investors certainly have to be happy with Infinity Pharmaceuticals, Inc. (INFI) and its short term performance
Infinity (INFI) Reports Narrower-than-Expected Loss in Q4
by Zacks Equity Research
Infinity (INFI) incurs narrower-than-expected Loss in Q4 and expects to report data from the monotherapy expansion and combination dose escalation components of its pipeline candidate IPI-549.
Infinity Provides Update on Lead Candidate, Issues 2018 View
by Zacks Equity Research
Infinity (INFI) announces the achievement of some development milestones for its lead pipeline candidate- IPI-549 and issued financial guidance for 2018.
Options Traders Expect Huge Moves in Infinity Pharmaceuticals (INFI) Stock
by Zacks Equity Research
Surging implied volatility makes Infinity Pharmaceuticals (INFI) stock lucrative to the option traders.
Infinity (INFI) Q3 Loss Narrower than Expected, View Intact
by Zacks Equity Research
Infinity Pharmaceuticals (INFI) Q3 loss was narrower than estimates and the year-ago quarter loss.
Seattle Genetics Inks Clinical Collaborations for Cancer Drug
by Zacks Equity Research
Seattle Genetics (SGEN) announced two clinical collaborations to evaluate SGN-LIV1A in triple negative breast cancer.
Infinity Pharmaceuticals, Inc. (INFI) in Focus: Stock Moves 12% Higher
by Zacks Equity Research
Infinity Pharmaceuticals, Inc. (INFI) saw its shares rise nearly 12% on the day.
Infinity/ Bristol-Myers Adds TNBC Patients to Clinical Deal
by Zacks Equity Research
Infinity (INFI) expanded its existing clinical collaboration with Bristol-Myers Squibb for evaluating IPI-549 in combination with Opdivo to include patients with triple negative breast cancer.
Infinity (INFI) Q2 Loss Wider than Expected, View Intact
by Zacks Equity Research
Infinity Pharmaceuticals, Inc. (INFI) reported a wider-than-expected loss in second-quarter 2017 due to the termination of an agreement with AbbVie.
Infinity Pharmaceuticals (INFI) Down 5.3% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Infinity Pharmaceuticals (INFI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Catalyst Pharmaceuticals (CPRX) Posts Loss as Expected in Q1
by Zacks Equity Research
Catalyst Pharmaceuticals, Inc. (CPRX) reported a loss of 6 cents per share in the first quarter of 2017, in line with the Zacks Consensus Estimate but narrower than the loss of 7 cents in the year-ago quarter.
Endocyte (ECYT) Reports Narrower-than-Expected Loss in Q1
by Zacks Equity Research
Endocyte, Inc. (ECYT) reported a narrower-than-expected loss in the first quarter of 2017.
Valeant (VRX) Q1 Earnings & Revenues Miss, View Raised
by Zacks Equity Research
Shares of Valeant Pharmaceuticals Inc. (VRX) surged significantly after the company raised the annual guidance for 2017 concurrent with the first-quarter 2017 earnings.
Infinity (INFI) Reports Narrower-than-Expected Loss in Q1
by Zacks Equity Research
Infinity Pharmaceuticals, Inc. (INFI) reported a loss of 21 cents per share in first-quarter 2017, narrower than the Zacks Consensus Estimate loss of 22 cents. Also, the company had reported loss of 82 cents in the year-ago quarter.
Endo (ENDP) Beats on Q1 Earnings, Reaffirms '17 Guidance
by Zacks Equity Research
Endo International plc's (ENDP) first-quarter 2017 earnings from continuing operations was $1.23 per share which topped the Zacks Consensus Estimate of $1.12. Earnings were also above the year-ago figure of $1.08.
Horizon (HZNP) Falls on Q1 Earnings Miss, Guidance Trimmed
by Zacks Equity Research
Horizon Pharma plc (HZNP) reported first-quarter 2017 earnings of 21 cents per share, down from 25 cents in the year-ago quarter. Reported earnings also missed the Zacks Consensus Estimate of 25 cents.
Catalent (CTLT) Shows Strength: Stock Adds 9.8% in Session
by Zacks Equity Research
Catalent, Inc. (CTLT) shares rose almost 10% in the last trading session.
Intercept (ICPT) Q1 Loss Narrower than Expected, Sales Beat
by Zacks Equity Research
Intercept Pharmaceuticals, Inc. (ICPT) posted a loss of $3.61 per share in the first quarter of 2017, narrower than the Zacks Consensus Estimate of a loss of $4.27.
Agenus (AGEN) Reports Narrower-than-Expected Loss in Q1
by Zacks Equity Research
Agenus Inc. (AGEN) reported first-quarter 2017 loss of 18 cents per share (including non-cash expenses), narrower than the Zacks Consensus Estimate of a loss of 32 cents and the year-ago loss of 37 cents.
Regeneron (REGN) Q1 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Regeneron Pharmaceuticals, Inc. (REGN) reported first-quarter 2017 results wherein earnings missed estimates while revenues beat expectations.